Drugs / NY-ESO-1 OLP4
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01810016 | Jan 2014 → May 2016 | metastatic melanoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
| Phase 1 | NCT00616941 | Mar 2008 → Jun 2011 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 OLP4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01810016 ↗ |
| Modality | Vaccine | “NY-ESO-1 OLP vaccine is safe and rapidly induces consistent integrated immune responses (antibody, CD8(+) and CD4(+)) in nearly all vaccinated patients when given with...” PMID 23032745 ↗ Oct 2012 |
| Route | Subcutaneous | “administered subcutaneously as a single injection” NCT00616941 ↗ |